<unk>  is a Ophthalmologic Agent that is FDA approved for the treatment of neovascular (wet) age-related macular degeneration.   Common adverse reactions include anterior chamber inflammation, blurred vision, cataract, conjunctival hemorrhage, corneal edema, eye discharge, eye irritation, eye pain, hypertension, increased intraocular pressure (IOP), ocular discomfort, punctate keratitis, reduced visual acuity, visual disturbance, vitreous floaters, and vitreous opacities..
Pegaptanib
Toceranib
Semaxanib
Pazopanib hydrochloride
Cediranib
Alectinib
Gilteritinib
Regorafenib